Skip to main content
OpenTrials
Completed

NCT Number: NCT01582321

Investigation of the Influence of Gender on Cardiovascular Function

Inflammation is a key initiating and damaging factor in many illnesses including infection, arthritis and cancer but also of particular relevance to this study in diseases of the heart and blood vessels (i.e. cardiovascular disease). Much evidence now exists demonstrating that male sex increases ones risk of cardiovascular disease. More recent evidence demonstrates that inflammatory responses in females appear to dampened in comparison to age matched males. Since inflammation is thought to be a key initiating phenomenon in many cardiovascular disease states the investigators will examine the differences in acute inflammatory responses between the sexes in healthy volunteers and the impact this has on the function of blood vessels.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

William Harvey Heart Centre, Barts & The London Medical School

London, EC1M 6BQ, United Kingdom

About this study

We now know that one of the earliest events involved in precipitating disease of the heart and blood vessels is the phenomenon of inflammation and that this inflammation is a key process involved in dampening the protective nature of the inner lining (the endothelium) of the blood vessel wall, called endothelial dysfunction. In healthy arteries the endothelium releases a number of factors that maintain the health of the blood vessel. These factors act to keep the blood vessel in an open and dilated state and prevent the furring up of the vessel by actively inhibiting the cell components of the blood from collecting at the endothelium and blocking the flow of blood through the artery. Recent research in animals has demonstrated that one of the key components of inflammation i.e. the attraction of white cells, is reduced in females compared to males and that this is due to a reduced expression of key proteins called 'adhesion molecules', an in particular a molecule called P-selectin, on the endothelium. We now wish to determine whether similar differences in white cell attraction and adhesion molecules exist between the sexes in humans and whether these differences might underlie differences in endothelial function.

To investigate this possibility we will conduct a study in two parts, using well validated models of acute inflammation in healthy volunteers.

Part 1 To determine whether responses to inflammation differ between sexes in part 1 we will use a cantharidin-induced model of acute inflammation. Previous published studies have shown when cantharidin is applied to the skin it causes acantholysis and blister formation. It is a safe, reproducible technique with no permanent scarring or ill-effects. We will study the effects on inflammatory responses by measuring the levels of cells and inflammatory mediators in blister fluids, urine and plasma. Participants will given two blisters that will be harvested at 24 hours (acute phase) and 72 hours (resolution phase) after cantharidin application. The effects of inflammation on blood vessels will also be studied through non invasive blood pressure measurements.

Part 2 To determine whether susceptibility to inflammation-induced endothelial dysfunction is distinct between the sexes in part 2 we will use typhoid vaccine to induce mild inflammation throughout the body including the blood vessels. Previous published studies have shown that vaccination induces an acute inflammation that results in a temporary (reversed within 48h) dysfunction of the endothelium that can be measured using a range of non-invasive techniques called ultrasound flow-mediated dilatation and pulse wave velocity. We will use these techniques together with biochemical measurements to determine possible associations of endothelial dysfunction with specific inflammatory factors. In particular we will investigate the possibility that differences in the expression of the adhesion molecule P-selectin might have a role to play in differences between the sexes.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Healthy subjects aged 18-45 who have volunteered themselves and are willing to sign the consent form.

Exclusion criteria

  • Healthy subjects unwilling to consent
  • History of hypertension, diabetes or hypertensive on BP measurement
  • Pregnant, or any possibility that a subject may be pregnant unless in the latter case a pregnancy test is performed with a negative result
  • History of any serious illnesses, including recent infections or trauma
  • Subjects taking systemic medication (other than the oral contraceptive pill)
  • Subjects with self-reported use of mouthwash or tongue scrapes
  • Subjects with recent or current antibiotic use
  • Subjects with a history, or recent treatment of (within last 3 months) of any oral condition (excluding caries), including gingivitis, periodontitis and halitosis.
  • Subjects that have recently participated (preceding 3 months) in any clinical studies involving administration of an inflammogen.

Treatment and study plan

Typhoid vaccine

Biological

The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution

Other names: Typhim Vi®

Cantharidin

Drug

0.1% cantharidin solution in acetone from 0.7% stock solution of cantharone is prepared and applied immediately. 10 μl of cantharidin per disc.

Other names: Cantharidin, cantharone 0.1%

Primary outcomes

  1. Comparison change in blister fluid total and differential leukocyte numbers (Part 1)

    Time frame: 24, 72 h

    plasma and fluid collected from the blisters at 24 hours (acute phase) and 72 hours (resolution phase) after the cantharidin application will be analysed using standard laboratory techniques including flow cytometry

  2. Flow-mediated dilatation (Part 2)

    Time frame: 0, 24, 48 h

    Flow mediated dilatation of the brachial artery will be assessed using ultrasound will be measured at time 0, 24 and 48h. At the 16h timepoint a single typhoid vaccination will be administered in the arm or buttock.

Secondary outcomes

  1. Blood pressure (Part 1)

    Time frame: 0, 48, 72 h

    Blood pressure will be measured every 15 minutes for 1 hour

  2. Platelet reactivity (Part 2)

    Time frame: 0, 24 and 48h

    Blood will be collected and platelet reactivity assessed using impedance aggreometry

  3. Platelet activation (Part 2)

    Time frame: 0,24 and 48h

    Blood will be collected and platelet p-selectin and platelet-monocyte expression determined using flow cytometry

  4. Arterial stiffness (Part 2)

    Time frame: 0, 24 and 48h

    The speed of blood pressure waves will be measured to give a pulse wave velocity measure for the aorta.

  5. Inflammatory cell expression (Part 1 and 2)

    Time frame: 0, 48, 72h part 1, 0, 24 and 48h part 2

    Blood will be collected and inflammatory cell populations determined using flow cytometry

  6. Blood inflammatory molecule expression (Part 1 and 2)

    Time frame: 0, 48, 72 h part 1, 0, 24 and 48h part 2,

    Plasma will be collected for assessment of inflammatory markers

Sponsors and collaborators

Lead sponsor

Queen Mary University of London

Other

Registry information

Official study title

Investigation of the Influence of Gender on Cardiovascular Function and Inflammation

Important dates

Study start
2012
Primary completion
2016
Study completion
2017
First posted
Apr 20, 2012
Registry last updated
Jun 14, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.